Additional work is needed to determine whether SCLC-P tumor subtypes, which express the highest levels of MYC across all SCLC subtypes, would benefit from KBTBD4 activation through UM171, which not only degrades CoREST complex proteins but also suppresses MYC expression (109, 114, 124). Here, MYC is linked to neoplasm.